Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
10.92
-0.37 (-3.28%)
At close: Oct 13, 2026, 4:00 PM EDT
11.13
+0.21 (1.92%)
After-hours: Oct 13, 2026, 7:30 PM EDT
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $477.35M in the half year ending June 30, 2026, with 99.22% growth. This brings the company's revenue in the last twelve months to $890.79M, up 167.52% year-over-year. In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth.
Revenue (ttm)
$890.79M
Revenue Growth
+167.52%
P/S Ratio
4.20
Revenue / Employee
$752,352
Employees
1,184
Market Cap
3.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Dec 31, 2023 | 332.98M | 224.03M | 205.64% |
| Dec 31, 2022 | 108.95M | 103.42M | 1,873.24% |
| Dec 31, 2021 | 5.52M | 1.51M | 37.53% |
| Dec 31, 2020 | 4.01M | 1.57M | 64.21% |
| Dec 31, 2019 | 2.44M | 2.31M | 1,680.88% |
| Dec 31, 2018 | 137.28K | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Acadia Pharmaceuticals | 1.14B |
| Arcutis Biotherapeutics | 463.98M |
| IDEAYA Biosciences | 234.13M |
| AbCellera Biologics | 66.17M |
| Tango Therapeutics | 53.81M |
| Relay Therapeutics | 10.35M |
| Xenon Pharmaceuticals | 7.50M |
TLX News
- 4 days ago - Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate Care - Nasdaq
- 4 days ago - Profound Medical enters co-education agreement with Telix Pharmaceuticals - TheFly
- 4 days ago - Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care - GlobeNewsWire
- 7 days ago - First U.S. Patient Receives Telix's Newly Approved Brain Cancer Imaging Drug - Nasdaq
- 7 days ago - Telix Pharmaceuticals’ brain cancer imaging drug applied on first U.S. patients - TheFly
- 7 days ago - First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18) - GlobeNewsWire
- 12 days ago - Ion Beam Enters Distribution Agreement For ARTMS' QIS Technology - Nasdaq
- 12 days ago - IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS® - GlobeNewsWire